3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder, Neurogenic
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Malnutrition
1
Head and Neck Neoplasms
1
Esophagitis
1
Endometriosis
1
Cystitis, Interstitial
1
Cystitis, Hemorrhagic
1
Carcinoma, Hepatocellular
1
Interventions
Etoposide
27
Carboplatin
26
atezolizumab
16
durvalumab
12
Cisplatin
10
Topotecan
9
Drug Therapy
9
PM 01183
7
pembrolizumab
5
Radiotherapy
5
Specimen Handling
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Injections
4
Immunotherapy
4
trilaciclib
3
toripalimab
3
Temozolomide
3
Radiosurgery
3
Bevacizumab
3
AMG 757
3
tislelizumab
2
monalizumab
2
irinotecan sucrosofate
2
enzalutamide
2
apatinib
2
Platinum
2
Nivolumab
2
Itraconazole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Small Cell Lung Carcinoma
×
Immunonutrition Diet
×
Clear all
NCT06840704
2026-04-02
Relief
Hunan Cancer Hospital
Phase 3
Recruiting
121 enrolled